Crinetics Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its common stock to eighteen new non-executive employees.

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner


Ernst & Young LLP announces that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner.

Crinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees.

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)


Crinetics announced initial findings from the development program of its second clinical product candidate, atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist.

Crinetics Presents New Data at ENDO 2024 that Increases that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly


Crinetics Pharmaceuticals presents new data from its clinical development program evaluating oral, once-daily investigational paltusotine in acromegaly.